🙏It was my pleasure to attend the portrait unveiling ceremony that the Foundation for the National Institutes of Health (FNIH) hosted for Norman "Ned" Sharpless, M.D., on the main NIH campus in Bethesda. Dr. Sharpless served with distinction in a variety of federal science roles, most notably as director of NIH's National Cancer Institute (NCI) from 2017-2022. During his tenure, he championed investigator-initiated science, advanced childhood cancer research, and promoted big data approaches to oncology, including the Childhood Cancer Data Initiative. Beyond that, Dr. Sharpless led top research on tumor suppressor genes, cellular senescence, aging, and cancer biology. America's understanding of cancer research is far better for Dr. Sharpless's service. 🔬

Chemotherapy and ionizing radiation are known to promote clonal hematopoiesis and its progression to leukemia. By inducing temporary quiescence of hematopoietic stem cells during external stress might we mitigate CH expansion? We address this through a collaboration with @AbdelWahablab @PuZhang09980432: nature.com/articles/s41588-0…. Excited to share this and some thoughts from a recent meeting in Hiroshima which puts this work in a broader perspective.

🩸 ASH Plenary Spotlight CDK4/6 inhibition may mitigate chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis. Across three randomized trials, trilaciclib reduced growth of DNA damage response CH clones during chemotherapy. In murine models: • CDK4/6 inhibition before carboplatin suppressed expansion of Trp53-mutant HSPCs • Quiescence of WT HSPCs was preserved • Increased apoptosis observed in Trp53-mutant cells These data suggest that inducing HSPC quiescence with CDK4/6 inhibition may be a strategy to reduce therapy-related myeloid neoplasm risk. #ASH25 #HemeTwitter #CH #tMN @ASH_hematology

This article from @KFFHealthNews is disinformation. It’s an insult to readers seeking honest reporting about NIH and misleads prospective patients who may need lifesaving care at @NIHClinicalCntr. Inpatient admissions at hospitals nationwide are in a long-term decline. But there was an abnormal drop at @NIHClinicalCntr when the Biden administration failed to return back to pre-Covid levels of clinical trials. Our data confirms this, and we’re restoring trial activities to where they should be. KFF lied to the public about @NIHClinicalCntr by cherry picking one number to fit a political agenda. We will continue to inform you when this happens.

🤠 👉🏽 🗽 news: I will be joining @nyulangone on September 1, 2025 as Director of the GI Cancer Center & Associate Director of Translational Research at @Perlmutter_CC. I am excited to start the next chapter of the Maitra Lab in NYC & build a strong GI cancer research program.

RT @ScottGottliebMD: 🧵 Twenty-five years ago, it was common to hear complaints about a “drug lag”—the perception that Europeans routinely e…

How the @NIH dominates the world’s health research — in charts. Great comments by @MiriamMerad nature.com/articles/d41586-0…

If we want to thoughtfully reduce NIH indirect costs, we need to reduce the federal regulatory burden that causes universities to hire so many administrators to remain compliant.

Every year, ~90,000 teens and young adults receive a cancer diagnosis. Programs like those at @UNC_Lineberger—an NCI-Designated Comprehensive Cancer Center—help young people navigate treatment, enroll in trials, and get fertility counseling. Read more: go.nih.gov/spJyrrI

Novocure and its Tumor Treating Fields (TTF) Modality meets its Phase 3 trial primary endpoint of improving survival in local advanced #PancreaticCancer (LAPC). Caveats are several: - modest improvement in survival (one of those statistically significant but “is it meaningful” improvements): 14.1 months to 16.2 months. Not Gem + Erlotinib level but not that far either. - the backbone is Gem Abraxane, not FOLFIRINOX which has shown overall survival longer than the TTF combo by itself in LAPC, if the patient can tolerate the therapy. In that regard this regimen might be beneficial in an older, less fit population of LAPC patients. - I guess we should always celebrate a phase 3 success in pancreatic cancer (especially in the challenging LAPC setting) although this is not a home run.

A single-cell atlas of aging tissue demonstrates shared multi-omics of aging and cancer hallmarks nature.com/articles/s43587-0… @NatureAging @jacksonlab @justsaysinmice @OlgaAnczukow

The rise of industry-sponsored cancer clinical trial enrollment from 2008 to 2022, now surpassing NIH-sponsored trials, highlights a shift in oncology research priorities. This trend may limit opportunities for addressing broader, patient-centered questions that are not commercially driven, potentially hindering progress in areas like prevention and survivorship. Check out our editorial @JCO_ASCO on Bridging the Gap in Cancer Clinical Trial Funding @nes047 @UNC_Lineberger ascopubs.org/doi/full/10.120…

A link to the editorial by @YAbdouMD @nes047 @UNC_Lineberger ascopubs.org/doi/full/10.120… worth reading!

Out in JCO: the ratio of enrollment to Industry- vs Federally-sponsored trials doubled between 2008-2022. This led to an acceleration in drug development, but less trials exploring de-escalation or non-drug-related questions. Great editorial by @YAbdouMD. ascopubs.org/doi/10.1200/JCO…

I'm excited to announce that @NCICCHE Director Dr. Sanya Springfield will be an acting deputy director at @theNCI – in this new role, she'll be charged with broadening and strengthening our cancer health equity and inclusion efforts. #EndingCancerAsWeKnowIt for all.

I'm honored to present #SCLC updates at the 2nd annual Thomas C. Shea Clinical Cancer Symposium on Monday, September 23rd from the @UNC_Lineberger cancer center alongside Drs. @DrJaredWeiss @JulieBrahmer Mark Socinski @nes047 and others! In person @The_Umstead in Cary, NC!

Leading the @AmericanCancer Society + @ACSCAN is the honor of a lifetime. Over the last 3.5 years, we increased our impact and focused on improving the lives of cancer patients. I love this org! With ACS on strong footing and having accomplished what I came to achieve, today I announce my plans to hand over the reins...more to come. pressroom.cancer.org/release…

So sad to hear about the passing of Jeff Weber, a giant in the field of oncology. He was involved in the early days of cytokine and cell therapy and most recently led studies of personalized vaccines for melanoma patients. I originally worked with Jeff @theNCI over 30 years ago. He was a great friend and colleague to many of us in the melanoma and immunotherapy field and we will remember him as a pioneer, thought leader and compassionate physician. @sitcancer @DrJamesMule @BernardAFox

RT @Aiims1742: Based on the ECLIPSE trial, @US_FDA today approved the Guardant SHIELD blood test for #ColorectalCancer. @matthewherper in…

"Our mission is to create the medicine of tomorrow. To develop treatments for people who do not have effective treatments today." – Dr. Steven Rosenberg, National Medal of Technology and Innovation Laureate